Journal publications

Export 80 results:
Author Title [ Type(Desc)] Year
Filters: Type is Journal Article  [Clear All Filters]
Journal Article
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Gifford RJM, de Oliveira T, Rambaut A, Myers R.E, Gale C.V, Dunn DT, Shafer R., Vandamme A.M, Kellam P, Pillay D.  2006.  Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS. 20:1521-9.
Schultze A, Paredes R, Sabin CA, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM et al..  2017.  The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.. Antivir Ther.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin CA, Nelson M, Winston A et al..  2017.  An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J Antimicrob Chemother.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2019.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.. J Virus Erad. 5(4):204-211.
Ragonnet-Cronin M, Hodcroft E, Hue S, Fearnhill E, Delpech V, Leigh Brown A, Lycett S.  2013.  Automated analysis of phylogenetic clusters. BMC Bioinformatics. 14:317.
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Collins IJ, Foster C, Tostevin A, Tookey P, Riordan A., Dunn DT, Gibb DM, Judd A.  2017.  Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clin Infect Dis. Epub ahead of print
Le Vu S, Ratmann O, Delpech V, Brown A, Gill NO, Tostevin A, Fraser C, Volz E.  2017.  Comparison of cluster-based and source-attribution methods for estimating transmission risk using large HIV sequence databases.. Epidemics.
Stirrup OT, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2020.  Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Med.
Hodcroft E, Hadfield J, Fearnhill E, Phillips AN, Dunn DT, O’Shea S, Pillay D, Leigh Brown A.  2014.  The contribution of viral genotype to plasma viral set-point in HIV infection. PLoS Pathog. 10:e1004112.
De Luca A., Dunn DT, Zazzi M, Camacho R., Torti C., Fanti I., Kaiser R., Sonnerborg A., Codoner F.M, Van Laethem K. et al..  2013.  Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 207:1216-20.
Hue S, Gifford RJM, Dunn DT, Fearnhill E, Pillay D.  2009.  Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naive individuals. J Virol. 83:2645-54.
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D et al..  2018.  Determining the origins of HIV-1 drug-resistant minority variants in people who are recently infected using phylogenetic reconstruction.. Clin Infect Dis.
Ragonnet-Cronin M, Shilaih M, Günthard HF, Hodcroft E, Boni J, Fearnhill E, Dunn DT, Yerly S, Klimait T, Aubert V et al..  2016.  A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Sci Rep. 6
Santoro MM, Sabin CA, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Nicastri E., Antinori AM, Palamara G et al..  2013.  Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med. 14:571-7.
Geretti AM, Harrison LJ, Green H, Sabin CA, Hill T, Fearnhill E, Pillay D, Dunn DT.  2009.  Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis. 48:1296-305.
Lodi S, Günthard HF, Dunn DT, Garcia F, Logan R, Jose S., Bucher HC, Scherrer AU, Schneider M-P, Egger M et al..  2018.  Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.. AIDS. 32(3):327-335.
Castro H, Pillay D, Sabin CA, Dunn DT.  2012.  Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC Med Res Methodol. 12:30.